Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCORT: hESC-derived Progenitors in Heart Failure
NCT02057900Phase 1Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2013
- Primary completion
- Mar 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Human embryonic stem cell-derived CD15+ Isl-1+ progenitors in Ischemic Heart Failure (IHF), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Number and nature of adverse events at 1 year. Started May 2013; status: completed.
02
Drugs
Human embryonic stem cell-derived CD15+ Isl-1+ progenitors
03
Conditions
Ischemic Heart Failure (IHF)
Beyond the preview
Go deeper on NCT02057900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057900.